10 Micro-, Small-Cap Firms Dominate Thursday’s Gains

4. OptiNose Inc. (NASDAQ:OPTN)

OptiNose grew its share prices by 52.50 percent on Thursday to finish at $9.15 apiece as investors took heart from news that it is set to be acquired by Paratek Pharmaceuticals for $330 million.

In a statement on Thursday, Paratek announced that it entered into a definitive merger agreement with OPTN, under which, Paratek will acquire OPTN, including its approved product XHANCE (fluticasone propionate).

After the transaction, OPTN shareholders will expect to receive $14 for each share, including the payment of contingent value rights (CVRs) tied to future commercial milestones.

According to Paratek, the acquisition plan would boost its commercial portfolio beyond the flagship antibiotic NUZYRA.

“We have long recognized the potential of XHANCE to transform how CRS is treated. We have been exploring opportunities to make more patients and doctors aware of XHANCE and the benefits it can offer to patients suffering from this common condition. Paratek, with its robust commercial and medical capabilities, has the potential to rapidly extend awareness of XHANCE to primary care providers who treat the majority of patients with CRS,” said OPTN CEO Ramy Mahmoud.